ERIS LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of ERIS LIFESCIENCES have increased by 11.15% YoY .
The Earnings Per Share (EPS) of ERIS LIFESCIENCES has decreased by -5.96 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ERIS LIFESCIENCES Last 5 Annual Financial Results
[BOM: 540596|NSE : ERIS]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹1,347 Cr | ₹1,212 Cr | ₹1,074 Cr | ₹982 Cr | ₹856 Cr |
| Expenses | ₹862 Cr | ₹781 Cr | ₹706 Cr | ₹637 Cr | ₹533 Cr |
| Operating Profit (Excl OI) | ₹485 Cr | ₹431 Cr | ₹368 Cr | ₹345 Cr | ₹322 Cr |
| Other Income | ₹26 Cr | ₹8.71 Cr | ₹16 Cr | ₹32 Cr | ₹26 Cr |
| Interest | ₹4.22 Cr | ₹1.98 Cr | ₹2.30 Cr | ₹23 Cr | ₹11 Cr |
| Depreciation | ₹65 Cr | ₹43 Cr | ₹50 Cr | ₹36 Cr | ₹26 Cr |
| Profit Before Tax | ₹442 Cr | ₹394 Cr | ₹331 Cr | ₹317 Cr | ₹312 Cr |
| Profit After Tax | ₹406 Cr | ₹355 Cr | ₹297 Cr | ₹291 Cr | ₹295 Cr |
| Consolidated Net Profit | ₹406 Cr | ₹355 Cr | ₹296 Cr | ₹291 Cr | ₹294 Cr |
| Earnings Per Share (Rs) | ₹28.10 | ₹29.88 | ₹26.16 | ₹21.84 | ₹21.15 |
| PAT Margin (%) | 21.20 | 29.09 | 28.53 | 27.61 | 29.64 |
| ROE(%) | 18.25 | 23.33 | 24.78 | 24.28 | 28.96 |
| ROCE(%) | 17.31 | 25.29 | 27.60 | 25.44 | 26.54 |
| Total Debt/Equity(x) | 0.38 | 0.02 | 0.00 | 0.00 | 0.15 |
Key Financials |
||
| Market Cap | : | ₹ 11,835.4 Cr |
| Revenue (TTM) | : | ₹ 1,861.0 Cr |
| Net Profit(TTM) | : | ₹ 378.9 Cr |
| EPS (TTM) | : | ₹ 27.9 |
| P/E (TTM) | : | 31.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ERIS LIFESCIENCES | -0.7% | -3.9% | 48.8% |
| SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
| CIPLA | 2.5% | 0.4% | 71.7% |
| DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
| ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
| DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
| MANKIND PHARMA | NA | NA | NA |
| TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
| LUPIN | 2.8% | 0% | 147.8% |
ERIS LIFESCIENCES Revenues
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 11.15 % |
| 5 Yr CAGR | 12.02 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,347 Cr | 11.15 | |
| Mar2022 | ₹1,212 Cr | 12.83 | |
| Mar2021 | ₹1,074 Cr | 9.36 | |
| Mar2020 | ₹982 Cr | 14.79 | |
| Mar2019 | ₹856 Cr | - | |
ERIS LIFESCIENCES Operating Profit
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 12.60 % |
| 5 Yr CAGR | 10.77 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹485 Cr | 12.60 | |
| Mar2022 | ₹431 Cr | 17.09 | |
| Mar2021 | ₹368 Cr | 6.61 | |
| Mar2020 | ₹345 Cr | 7.13 | |
| Mar2019 | ₹322 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 1.32 % |
| 5 Yr CAGR | -1.11 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 36.01% | 1.32 | |
| Mar2022 | 35.54% | 3.77 | |
| Mar2021 | 34.25% | -2.50 | |
| Mar2020 | 35.13% | -6.69 | |
| Mar2019 | 37.65% | - | |
ERIS LIFESCIENCES Profit After Tax
[BOM: 540596|NSE : ERIS]
| Y-o-Y | 14.35 % |
| 5 Yr CAGR | 8.40 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹406 Cr | 14.35 | |
| Mar2022 | ₹355 Cr | 19.78 | |
| Mar2021 | ₹296 Cr | 1.96 | |
| Mar2020 | ₹291 Cr | -1.13 | |
| Mar2019 | ₹294 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -27.12 % |
| 5 Yr CAGR | -8.04 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 21.2 % | -27.12 | |
| Mar2022 | 29.09 % | 1.96 | |
| Mar2021 | 28.53 % | 3.33 | |
| Mar2020 | 27.61 % | -6.85 | |
| Mar2019 | 29.64 % | - | |
ERIS LIFESCIENCES Earnings Per Share (EPS)
[BOM: 540596|NSE : ERIS]
| Y-o-Y | -5.96 % |
| 5 Yr CAGR | 7.36 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹28 | -5.96 | |
| Mar2022 | ₹30 | 14.22 | |
| Mar2021 | ₹26 | 19.78 | |
| Mar2020 | ₹22 | 3.26 | |
| Mar2019 | ₹21 | - | |
ERIS LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 540596|NSE : ERIS]
| Y-o-Y | -31.55 % |
| 5 Yr CAGR | -10.13 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 17.31% | -31.55 | |
| Mar2022 | 25.29% | -8.37 | |
| Mar2021 | 27.6% | 8.49 | |
| Mar2020 | 25.44% | -4.14 | |
| Mar2019 | 26.54% | - | |
ERIS LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹870.3 |
| Current MarketCap | : | ₹ 11,835.4 Cr |
| Updated EOD on | : | Apr 18,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ERIS LIFESCIENCES | -0.7% |
-3.9% |
48.8% |
| SENSEX | -2.9% |
-0.4% |
20% |
ERIS LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE 250 SMALLCAP | -0.9% | 12.1% | 61.4% |
| S&P BSE SMALL CAP | -1.1% | 11.8% | 62% |
| S&P BSE 400 MIDSMALLCAP | -1.2% | 8.6% | 57.2% |
| S&P BSE MIDSMALLCAP | -1.2% | 9.4% | 62.3% |
| S&P BSE ALLCAP | -2.2% | 3.9% | 37% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP250 | -0.7% | 12.7% | 67.3% |
| NIFTY MID SMALL400 | -1.2% | 9.2% | 59.9% |
| NIFTY500 MULTICAP 50:25:25 | -1.8% | 5.7% | 44.8% |
| NIFTY 500 | -2.2% | 3.5% | 36% |
You may also like the below Video Courses
FAQ about ERIS LIFESCIENCES Financials
How the annual revenues of ERIS LIFESCIENCES have changed ?
The Revenues of ERIS LIFESCIENCES have increased by 11.15% YoY .
How the Earnings per Share (EPS) of ERIS LIFESCIENCES have changed?
The Earnings Per Share (EPS) of ERIS LIFESCIENCES has decreased by -5.96 % YoY .
Check out Intrinsic Value of Peers of ERIS LIFESCIENCES
Compare Stock Analytics of Peers of ERIS LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
